3Plunkett TA ,Smith P,Rubens RD. Risk of complications from bone metastases in breast cancer implications for management [J]. Eur J Cancer, 2000,36(4) :476.
4Shoskes D A. Use of antibiotics in chronic prostatitis syn- dromes[J]. CanJ Uorl, 2010, 8(1): 24.
5Nudo R, Wise B, Sifuente S, et al. Neural substrates for the effect of rehabilitative training on motor recovery after is- chemic infarct[J]. Science, 2012, 272: 1791.
6Cuneyt Ozden, Ozdem Levent Ozdal, Guvenc Urgancioglu. Correlation between Metabolic Syndrome and Prostatic Growth in Benign Prostatic Hyperp|asia[J ] european urolo- gy, 2010, 51: 199.
7Ozden C, Ozdal O L, Urqancioqlu G, et al. The correlation Between metabolic syndrome and prostatic growth in patients with benign prostatic hyperpl&sia[J]. Eur Urol, 2009, 51 (1): 199.
8Murray CJL,Lopez AD.Measuring the global burden of disease.New England Journal of Medicine,2013,369(5):448-457.
9Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016,66(2): 115-132.
10Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors[J].J Clin Oncol, 2005,23(34): 8580-8587.
